Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Phase 1 Pharmacodynamic Study
Interventions: Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray; Drug
Lead sponsor: Tarsa Therapeutics, Inc.; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
Interventions: Kidney Biopsy, MRI, Retina Scan; Procedure · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 9 more

Conditions: Healthy
Interventions: Dextromethorphan HBr, GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: HM12460A; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions: Estradiol or Placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy Volunteers
Interventions: RO7049389, Pitavastatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Participants
Interventions: Vonoprazan, Rifampin; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Shortness of Breath, Shortness of Breath/Dyspnea, Respiratory Distress
Interventions: Multiple Inhalation Breathing Pattern, Tactical Breathing Technique; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Crohn's Disease
Interventions: GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C, GSK1605786 GSK modified-process: formulation D, GSK1605786 GSK tablet: formulation E; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: TKI258; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 11 more

Conditions: Healthy Subjects
Interventions: E2027, Diltiazem ER; Drug
Lead sponsor: Eisai Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Pain
Interventions: Spinal cord stimulator; Device
Lead sponsor: The Center for Clinical Research, Winston-Salem, NC; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Antithrombotic
Interventions: Enoxaparin, unfractionated heparin (UFH), BMS-986177; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota

Conditions: Solid Tumor, Adult
Interventions: eFT226, Sotorasib, Fulvestrant, Abemaciclib, Trastuzumab; Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 10 more

Conditions: Healthy
Interventions: PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson Disease
Interventions: Flumazenil, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Small RNA sequencing, PRECEPT assay (qRT-PCR validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Respiratory Depression
Interventions: Remifentanil, Oxygen, Carbon dioxide; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Visual Acuity
Interventions: ACUVUE OASYS® 1-Day for Astigmatism - TAM 24, ACUVUE OASYS® 1-Day for Astigmatism; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 5
States / cities: Longwood, Florida • Bloomington, Illinois • Pittsburg, Kansas + 2 more

Conditions: Diabetes Mellitus
Interventions: insulin glargine, insulin glulisine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Neoplasm Metastases
Interventions: Sequence 1, Sequence 2; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: Teduglutide, Syringe Injection, Pen injector; Drug · Device
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Urinary Incontinence
Interventions: PureWick® Urine Collection System, UltraFlex™ Self-Adhering Male External Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 65 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Greenacres City, Florida • Hamilton, New Jersey

Search by objective public record fields.

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

Kidney Precision Medicine Project

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Molar Potency Study of HM12460A in Healthy Subjects

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers

Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

Training Strategies to Maintain Performance

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects

Comparison of 1000 Hertz (Hz), Burst, and Standard Spinal Cord Stimulation in Chronic Pain Relief

A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers

Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

Predictors of Opioid-Induced Respiratory Depression (OIRD)

Evaluation of ACUVUE OASYS® 1-Day for Astigmatism Lenses Produced on a New Manufacturing Line

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.